Search

NICE recommends ibrutinib for relapsed or refractory mantle cell lymphoma

Standard post

… mantle cell lymphoma that has relapsed (come back) or was refractory (didn’t respond) to previous treatments. Mantle … after it has been treated. People with relapsed and refractory mantle cell lymphoma have very limited treatment …  recommending ibrutinib to treat people with relapsed and refractory mantle cell lymphoma if they have had only one …

Polatuzumab vedotin improves outcomes for people with relapsed or refractory DLBCL

Standard post

… that has come back ( relapsed ) or has not responded ( refractory ) after previous treatment and who are not … trial, the results are positive. People with relapsed or refractory DLBCL currently who aren’t able to have a stem … of patients with transplantation ineligible relapsed or refractory DLBCL.  Study authors Larger trials of …

Promising results of oral chemotherapy drug for refractory low-grade NHL

Standard post

… low-grade non-Hodgkin lymphomas who have not responded ( refractory ) to previous treatment. Duvelisib is a … may provide a new oral treatment option for people with refractory low-grade non-Hodgkin lymphomas, many of whom are … … Promising results of oral chemotherapy drug for refractory low-grade NHL …

New treatment options for lymphoma in Scotland

Standard post

… lymphoma that has come back (relapsed) or not responded (refractory) to previous treatment ibrutinib plus rituximab … is now available on the NHS in Scotland for relapsed or refractory follicular lymphoma, while ibrutinib has been approved for NHS use in people with relapsed or refractory Waldenström’s macroglobulinaemia. … New treatment …

Early results of phase 2 trial of polatuzumab vedotin for DLBCL

Standard post

… containing polatuzumab vedotin in people with relapsed or refractory lymphoma has announced promising early results. … that has come back ( relapsed ) or has not responded ( refractory ) to other treatment: polatuzumab vedotin, … year. The study showed that in people with relapsed or refractory follicular lymphoma, outcomes were similar in all …

NICE recommends pembrolizumab for Hodgkin lymphoma

Standard post

… has recommended pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma for people aged 3 years … for lymphoma. … New treatment available for relapsed or refractory classical Hodgkin lymphoma. … NICE recommends …

NICE to recommend venetoclax with rituximab for CLL

Standard post

… leukaemia (CLL) that has not responded to treatment ( refractory ) or has come back after treatment ( relapsed ). … on the NHS is positive news for people with relapsed or refractory CLL in England. … Venetoclax plus rituximab is now available on the NHS for adults with relapsed or refractory CLL … NICE to recommend venetoclax with rituximab …

NICE recommends epcoritamab for DLBCL

Standard post

… epcoritamab as an option for treating relapsed or refractory  diffuse large B-cell lymphoma (DLBCL)  in adults … for lymphoma. … New treatment available for relapsed or refractory diffuse large B-cell lymphoma. … NICE recommends …

NICE recommends glofitamab for DLBCL

Standard post

… glofitamab as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults … for lymphoma.   … New treatment available for relapsed or refractory diffuse large B-cell lymphoma. … NICE recommends …